The Eclipse Of A Star
Outlook Business|March 29, 2019

Investors worry about poor corporate governance practices at Sun Pharma and price erosion in the US generics market.

Prathamesh Mulye
The Eclipse Of A Star

The question was raised quietly but it weighs heavy, especially on a market leader that has been under attack over the past few months. In two notes, dated January 28 and February 18, the Securities and Exchange Board of India (Sebi) asked Sun Pharma to explain a “diversion of 420 billion to a pharma distribution company Aditya Medisales (AML)”, according to media reports. This was reported by a business daily on March 6. The Dilip Shanghvi-led company has dismissed the allegation as baseless, but the niggling questions on corporate governance practices at the pharma major, which started last September, seem to be compounding.

On December 3, 2018, Shanghvi had decided to break his silence holding a conference call. While this was meant to calm the nerves of investors, his responses, in fact, made matters worse.

Following his interaction with analysts, the market capitalisation of Sun Pharma fell below 1-trillion mark for the first time since August 2013. In two days, investors of Sun Pharma ended up losing 110 billion with the stock hitting a six-year low of 375. The stock price has marginally recovered to 455 as of March 8 on the back of better-than-expected third quarter results but the overhang is still clearly visible. At its peak, Sun Pharma’s market capitalisation had reached above 2.5 trillion, propelling Shanghvi to replace Mukesh Ambani for the title of the wealthiest Indian. But now “a massive wealth destruction has taken place. The stock has fallen by more than 60% in the past five years post the Ranbaxy acquisition,” says Jeena Scriptech Alpha Advisors’ managing director Gaurav A Parikh.

The viral circulation of the Australian brokerage firm Macquarie’s note Murky Waters of Sun Pharma last September and complaints of a whistleblower — raised last November about corporate governance practices at the company — dented the pharma giant’s reputation.

This story is from the March 29, 2019 edition of Outlook Business.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.

This story is from the March 29, 2019 edition of Outlook Business.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.

MORE STORIES FROM OUTLOOK BUSINESSView All
THE JOY OF ADJUSTING A LITTLE
Outlook Business

THE JOY OF ADJUSTING A LITTLE

Partha DeSarkar, executive director and CEO of Hinduja Global Solutions, not only advocates making small adjustments but also taking oneself less seriously to remain happy

time-read
2 mins  |
April 2024
MONEY PLANT
Outlook Business

MONEY PLANT

Firms are popping up to help people and companies plant saplings. Reasons for this green consciousness range from earning carbon credits to a desire to fight deforestation

time-read
5 mins  |
April 2024
AI'S NEW PORN POSITION
Outlook Business

AI'S NEW PORN POSITION

Deepfakes and artificial intelligence-generated images have breathed new life into the porn industry. Celebrities have become the latest victims and revenge porn is on the rise

time-read
8 mins  |
April 2024
HOUSE OF CARDS
Outlook Business

HOUSE OF CARDS

At 8.4%, India’s GDP surpassed the expectations of analysts of almost all dispositions. But are GDP numbers hiding a bleaker story? It is not just the missing private money, there are more devils in the story

time-read
7 mins  |
April 2024
'Markets Can See More Price Correction in the Coming Quarters'
Outlook Business

'Markets Can See More Price Correction in the Coming Quarters'

Sunil Koul, executive director Asia Pacific portfolio strategy, global macro research) at Goldman Sachs, in an exclusive interview with Ayaan Kartik and Neeraj Thakur, talks about the valuation situation in India and how foreign investors are looking at increasing their bets in the equity markets

time-read
4 mins  |
April 2024
MARKETS, RETAIL INVESTORS TANGO TO NEW HIGHS
Outlook Business

MARKETS, RETAIL INVESTORS TANGO TO NEW HIGHS

As more investors enter the markets, the palette of investing style becomes more colourful. Each investor brings in their own biases, impulsive actions and assumptions to the markets.

time-read
4 mins  |
April 2024
GREED OVER FUNDAMENTALS: THE INVESTOR'S FOLLY
Outlook Business

GREED OVER FUNDAMENTALS: THE INVESTOR'S FOLLY

In her address at the fifth SEBI-NISM research conference on March 12, 2024, Securities and Exchange Board of India (SEBI) chief Madhabi Puri Buch expressed her concerns about the valuation froth in the mid- and small-cap space.

time-read
4 mins  |
April 2024
WINNING THE GAME OF BULLS AND BEARS
Outlook Business

WINNING THE GAME OF BULLS AND BEARS

While retail investors rushed to make hay as smalland mid-cap stocks shone at the bourses, institutional investors stayed away, guided by traditional wisdom that warned them against the exuberance in the stock market. The mid-March crash, dominated by the smaller segments, proved their point

time-read
3 mins  |
April 2024
DELIRIUM IN THE MARKETS
Outlook Business

DELIRIUM IN THE MARKETS

Market regulator SEBI says there is froth” in the mid-and small-cap stocks; banker Uday Kotak says there is no bubble. Caught in this cross-current are traders in small towns who are betting heavily in risky derivatives. What is next for the turbocharged Indian markets and what of the retail investors rallying behind it?

time-read
10+ mins  |
April 2024
Dynamic Women Achievers
Outlook Business

Dynamic Women Achievers

Discover the vibrant narratives of dynamic women achievers breaking barriers and reshaping the landscape across diverse fields. From trailblazing entrepreneurs to influential thought leaders, this article celebrates the resilience, innovation, and impactful contributions of women who defy norms, inspiring a new era of empowerment and progress.

time-read
6 mins  |
March 2024